Nuvaring (Ethinylestradiol, Etonogestrel)

Ethinylestradiol, the active ingredient in NuvaRing, is a combined estrogen‑progestogen contraceptive presented as a 0.015 mg ethinylestradiol and 0.12 mg etonogestrel vaginal ring for vaginal use. It prevents pregnancy in women of reproductive age and is prescribed as a reversible hormonal birth‑control method.

GNH USA supplies NuvaRing as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

NuvaRing, a combined estrogen‑progestogen contraceptive, is used to prevent pregnancy. Contraception: provides effective reversible birth control to prevent pregnancy in women of reproductive age. Family planning: enables women to plan and space pregnancies according to personal goals. Hormonal birth control: delivers continuous low‑dose hormones to suppress ovulation and alter cervical mucus.

NuvaRing may cause a range of adverse reactions, varying in frequency and severity. Common Side Effects: - Headache: mild to moderate pain often occurring during the initial cycles. - Nausea: occasional stomach upset that usually resolves with continued use. - Breast tenderness: swelling or discomfort of the breasts. - Vaginal irritation: itching or discharge at the insertion site. - Mood changes: fluctuations in emotional state or irritability. - Spotting or breakthrough bleeding: irregular light bleeding between cycles.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism, requiring immediate medical attention. - Hepatic dysfunction: jaundice, liver enzyme elevation, or cholestasis. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hypertension: significant increase in blood pressure. - Cardiovascular events: stroke or myocardial infarction in high‑risk individuals.

Before prescribing NuvaRing, clinicians should consider several precautionary measures to ensure patient safety. Contraindicated in pregnancy: the product must not be used by women who are pregnant. History of thromboembolic disorders: avoid use in patients with past blood clots. Current estrogen‑containing therapy: do not combine with other estrogen products. Breast cancer history: contraindicated in women with active or past breast cancer. Smoking in women over 35 years: increased risk of cardiovascular events. Store at room temperature: keep in original packaging, protect from moisture and heat.

NuvaRing can interact with other medicines, altering its effectiveness or increasing side‑effect risk. Major Interactions (Avoid): - Rifampin, carbamazepine, phenytoin: enzyme inducers that may markedly reduce contraceptive efficacy. - Ketoconazole, itraconazole: potent CYP3A4 inhibitors that can increase hormone levels and risk of adverse events. - Protease inhibitors (e.g., ritonavir): may elevate plasma concentrations of ethinylestradiol.

Moderate Interactions (Monitor Closely): - Antibiotics such as tetracycline or metronidazole: may slightly diminish contraceptive effect. - Herbal supplements (e.g., St. John’s wort, ginseng): could reduce hormone levels. - Antidepressants (SSRIs): may increase risk of mood‑related side effects. - Antifungal azoles (e.g., fluconazole): may modestly raise hormone exposure. - Antihypertensives (e.g., ACE inhibitors): monitor blood pressure changes.